Clinical Trials
317 trialsSintilimab Plus Chemotherapy as Induction Therapy for Unresectable Stage IIIC NSCLC
Sun Yat-sen University
Short-Course Radiotherapy Followed by Immunotherapy Combined With Chemotherapy for Microsatellite Stable Locally Advanced Rectal Cancer: A Prospective, Randomized, Controlled Phase II Clinical Trial
Tianjin Medical University Cancer Institute and Hospital
Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.
The First Affiliated Hospital with Nanjing Medical University
The DoHAICs Study Expansion Phase
Tianjin Medical University Cancer Institute and Hospital
Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer
Sichuan University
Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma
Sun Yat-sen University
Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer
Shandong Cancer Hospital and Institute
Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)
Sun Yat-sen University
SACTION 2501
Sun Yat-sen University
Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases
Shandong Cancer Hospital and Institute
CASINOs
Jinhua Central Hospital
NIBCUN
Sun Yat-sen University
HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)
Fudan University
BEST
Shanghai Zhongshan Hospital
Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer
Tongji Hospital
Denosumab Strategy for Liver Cancer With Bone Metastases
Tongji Hospital
Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma
Tongji Hospital
A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer
Tianjin Medical University Cancer Institute and Hospital
Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma
Fudan University
Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Sincerely20
Fudan University
NeoSACT
Guangdong Provincial People's Hospital
Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)
Ruijin Hospital
K-NADIR
The First Affiliated Hospital of Guangzhou Medical University
A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma
Fudan University
Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC
First Affiliated Hospital of Guangxi Medical University
SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
FEMUS
Fudan University
TRIUNITE-08
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Sintilimab in Cancer of Unknown Primary
M.D. Anderson Cancer Center
Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer
Peking Union Medical College Hospital
Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer
Shanghai Changzheng Hospital
Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma
Sun Yat-sen University
Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)
First Affiliated Hospital of Zhejiang University
HAIC Combined With Donafenib and Sintilimab for Unresectable ICC
Zhongda Hospital
CTONG 2508
Guangdong Association of Clinical Trials
ESO-Nanjing7
Jiangsu Cancer Institute & Hospital
Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma
Sun Yat-sen University
Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer
Sichuan University
Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma
Hebei Medical University Fourth Hospital
ARTEMIS-GC3
The First Affiliated Hospital with Nanjing Medical University
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
Peking Union Medical College Hospital
CISN-L
First Affiliated Hospital of Wenzhou Medical University
NLCCRIT-LARC
Peking University People's Hospital
Remission
Fudan University
Clinical Study to Evaluate the Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin and Sintilimab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences